The commonly used food additive monosodium glutamate (MSG)
has been linked to obesity and disorders associated with the metabolic syndrome
including progressive liver disease. A new study that identifies MSG as a
critical factor in the initiation of obesity and shows that a restrictive diet
cannot counteract this effect but can slow the progression of related liver
disease is published in Journal of Medicinal Food, a peer-reviewed journal from
Mary Ann Liebert, Inc., publishers. The paper is available on the Journal of
Medicinal Food website.
Makoto Fujimoto and a team of international researchers from
Japan, the U.S., and Italy monitored the weight gain and development of
nonalcoholic fatty liver disease and its progression to nonalcoholic
steatohepatitis in MSG-treated mice fed either a calorie-restricted or regular
diet. They report their findings in the article "A Dietary Restriction
Influences the Progression But Not the Initiation of MSG-Induced Nonalcoholic
Steatohepatitis."
No comments:
Post a Comment